These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2883502)

  • 1. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis.
    Leibundgut U; Lancranjan I
    Lancet; 1987 May; 1(8543):1198. PubMed ID: 2883502
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of emesis by tropisetron in children receiving combined chemotherapy with cisplatin.
    Berberoglu S
    Pediatr Hematol Oncol; 1995; 12(5):479-83. PubMed ID: 8519633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of emesis by ICS 205-930 in children receiving cytotoxic chemotherapy.
    Hachimi-Idrissi S; De Schepper J; Maurus R; Otten J
    Eur J Cancer; 1993; 29A(6):854-6. PubMed ID: 8484976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tropisetron (ICS 205-930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide-based treatments.
    Cefalo G; Rottoli L; Armiraglio A; Pagan MG
    Am J Pediatr Hematol Oncol; 1994 Aug; 16(3):242-5. PubMed ID: 8037343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
    Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
    Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
    Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Simpson K; Spencer CM; McClellan KJ
    Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tropisetron hydrochloride in preventing and treating chemotherapy-induced nausea and vomiting: a phase II, randomized, multicenter, double-blinded, comparative clinical trial].
    Zhang WD; Wang XW; Chen ZD; Qin FZ; Shu YQ; Pan LX; Zhang MH
    Ai Zheng; 2007 Aug; 26(8):870-3. PubMed ID: 17697550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
    Ishioka S; Sagae S; Saito T; Kiya T; Sugimura M; Akutagawa N; Umemura K; Ito E; Kudo R
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):593-8. PubMed ID: 10791002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron.
    Schröder CP; van der Graaf WT; Kema IP; Groenewegen A; Sleijfer DT; de Vries EG
    Cancer Chemother Pharmacol; 1995; 36(6):477-82. PubMed ID: 7554039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study.
    de Boer M; de Wit R; Stoter G; Verweij J
    J Cancer Res Clin Oncol; 1995; 121(2):126-7. PubMed ID: 7883775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children.
    Gershanovich M; Kolygin B; Pirgach N
    Ann Oncol; 1993; 4 Suppl 3():35-7. PubMed ID: 8363998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of nausea and vomiting in cisplatin-treated patients by a selective 5-hydroxytryptamine (5-HT3) receptor antagonist, ICS 205-930.
    Dogliotti L; Faggiuolo R; Berruti A; Antonacci RA; Ortega C; Lancranjan I
    Tumori; 1990 Dec; 76(6):595-8. PubMed ID: 2284699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tropisetron, a new 5-HT3 receptor antagonist, in the prevention of radiation-induced emesis.
    Sorbe B; Berglind AM; de Bruijn K
    Radiother Oncol; 1992 Feb; 23(2):131-2. PubMed ID: 1546189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compassionate use of tropisetron in patients at high risk of severe emesis.
    Bleiberg H; Van Belle S; Paridaens R; De Wasch G; Dirix LY; Tjean M
    Ann Oncol; 1993; 4 Suppl 3():43-5. PubMed ID: 8364000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tropisetron (Navoban) in the control of nausea and vomiting induced by combined cancer chemotherapy in children.
    Ozkan A; Yildiz I; Yüksel L; Apak H; Celkan T
    Jpn J Clin Oncol; 1999 Feb; 29(2):92-5. PubMed ID: 10089950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.